Citibank upgraded its price target while Deutsche Bank maintained a negative rating for AstraZeneca.
1 report, 1 independent
Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citibank upgraded its price target while Deutsche Bank maintained a negative rating for AstraZeneca.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
company in Osaka, Japan
Nothing else this week.
-
Citibank
American multinational bank
-
Deutsche Bank
German global banking and financial services company
Related events
- Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.
- Deutsche Bank downgraded stock and Needham cut price targets citing safety concerns regarding Xenon's product ahead of its NDA meeting.
- Deutsche Bank reiterated a buy rating and price objective, while Citigroup and Jefferies Financial Group issued buy ratings and price targets for an unnamed company.
- Deutsche Bank lifted its price target on ABM on September 22, 2026.
Coverage
Newest first; wire copies grouped- proactiveinvestors.co.ukAstraZeneca's drug pipeine is splitting opinion among City analysts